CD8A and neoplasm: These studies revealed, among other things, that an efficient immune response against cancer requires the activation of tumor-specific CD8+ T cells directed against tumor-associated antigens [12,13], and that patients with advanced solid tumors either present tumors with evidence (“hot” immune-sensitive tumors) or without evidence (“cold” immune-resistant tumors) for a T-cell inflamed tumor microenvironment [14,15].